Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 12/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490757 | 0.87 | BRD4 (0.38) | EPHX1EPHX2BRD4 | |
| SCHEMBL1490809 | 0.86 | — | — | |
| SCHEMBL1490250 | 0.83 | EPHX1 (0.39) | EPHX1EPHX2BRD4 | |
| SCHEMBL1490575 | 0.82 | BRD4 (0.35) | BRD4 | |
| SCHEMBL1490240 | 0.80 | HTR1A (0.41) | BRD4 | |
| SCHEMBL1490732 | 0.78 | TLR7 (0.42) | — | |
| SCHEMBL5030333 | 0.75 | EPHX1 (0.36) | EPHX1EPHX2 | |
| SCHEMBL5030401 | 0.74 | EPHX1 (0.38) | EPHX1 | |
| SCHEMBL5034584 | 0.72 | EPHX1 (0.36) | EPHX1EPHX2BRD4 | |
| SCHEMBL1490787 | 0.69 | HTR1A (0.37) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897767-B2 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | IFNG, IL2, IRF3 | EPHX1 543/4885EPHX2 723/4885BRD4 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.